Post-earnings recap
Reported
Mon, Aug 7, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Krystal Biotech is struggling to meet expectations, particularly in terms of EPS. The stock's decline of 12.63% reflects investor disappointment, especially given the significant EPS miss. Without revenue figures or guidance, uncertainty remains about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.25 | N/A | -197.62% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to advancing their pipeline despite the lack of financial guidance.
Management did not provide specific guidance for future performance.
The company is focused on ongoing clinical trials and product development.